- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01486446
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Your role in the study would include:
- Travelling to the clinic (in Anniston, Alabama, USA) for 3 out-patient visits, each lasting approximately 1 day
- Travelling and staying in the clinic for 2 in-patient stays:
- For the first in-patient visit you will have to spend 8 days and 7 nights in the clinic
- For the second in-patient visit you will have to spend 2 days and 1 night in the clinic You can bring books, laptops and DVDs to the clinic.
If you do not live within driving distance to the clinic you will need to stay in the local area (in Anniston, at a local hotel) for 1 to 2 weeks while you use the ointment, in addition to the in-patient portion of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Anniston, Alabama, United States, 36201
- Pinnacle Research Group, LLC.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must have a Body Mass Index (BMI) of 18-40 kg/m2 (inclusive)
- Have primary or inherited erythromelalgia (IEM)
- Experience flares of pain in your feet or hands caused by erythromelalgia
- Be generally healthy (apart from your pain)
- Stop taking your usual pain medications and certain other medications for up to 11.5 weeks
- Not be pregnant or breast-feeding
- Must be able and willing to provide informed consent and willing to comply with all study procedures and restrictions
Exclusion Criteria:
- Must not be in constant pain (must not continually be in moderate pain, 3/10 or more)
- Coexistent source of pain from other conditions that may interfere with the study interpretation
- HIV, Hepatitis B or C
- Treatment for significant depression within 6 months of Screening
- Not willing to use adequate contraception
- Alcoholism, alcohol or substance abuse
- Presence or history of major psychiatric disturbance
- Any other condition or finding that may pose undue risk for participation
- Use of any other investigational drug in the 30 days prior to dosing
- Donation or loss of whole blood or plasma prior to dosing as follows: 50 mL to 499 mL within 30 days, or more than 499 mL within 56 days
- Employee or relative of an employee who is directly involved in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: XPF-002
XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
|
XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
|
Placebo Comparator: Placebo
XEN402 0% w/w ointment for topical application.
Identical content and appearance to the XPF-002 ointment but without the active medicine.
Applied to the skin twice daily for 14 or 21 days.
|
XEN402 0% w/w ointment for topical application.
Identical content and appearance to the XPF-002 ointment but without the active medicine.
Applied to the skin twice daily for 14 or 21 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2
Time Frame: 14-21 Days
|
Using diary cards, subjects recorded the use of all non-pharmacological cooling methods used to relieve their erythromelalgia (EM) pain each day during Treatment Period 2. A smaller average number of cooling uses each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa. |
14-21 Days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Cooling Duration (Minutes Per Day) for EM-related Pain in Treatment Period 2
Time Frame: 14-21 Days
|
Using diary cards, subjects recorded the use and duration of all non-pharmacological cooling methods used to relieve their EM pain each day during Treatment Period 2. A smaller average duration of cooling each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa. |
14-21 Days
|
Time to Exit (Minutes) From Standard Heat Inductions in Treatment Period 1, Compared to Baseline
Time Frame: Baseline to Day 5
|
A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure. The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the heating procedure was stopped. This time is known as "Time to Exit". A longer Time to Exit compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment. |
Baseline to Day 5
|
Time to Exit (Minutes) From Standard Heat Inductions in Treatment Period 2, Compared to Baseline
Time Frame: Baseline and 14 or 21 days
|
A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure. The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the heating procedure was stopped. This time is known as "Time to Exit". A longer Time to Exit compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment. |
Baseline and 14 or 21 days
|
Time to Moderate Pain (Minutes) During Standard Heat Inductions in Treatment Period 1, Compared to Baseline
Time Frame: Baseline to Day 5
|
A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure. The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the subject recorded a pain intensity numerical score of 5 or more (on a scale of 0-10). This time is known as "Time to Moderate Pain". A longer Time to Moderate Pain compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment. |
Baseline to Day 5
|
Time to Moderate Pain (Minutes) During Standard Heat Inductions in Treatment Period 2, Compared to Baseline
Time Frame: Baseline and 14 or 21 days
|
A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure. The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the subject recorded a pain intensity numerical score of 5 or more (on a scale of 0-10). This time is known as "Time to Moderate Pain". A longer Time to Moderate Pain compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment. |
Baseline and 14 or 21 days
|
Daily Pain (Maximum Pain Intensity) in Treatment Period 2, Compared to Baseline
Time Frame: Baseline to 14 or 21 days
|
During Baseline and Treatment Period 2, subjects recorded pain scores in their diary cards 3 times each day (upon waking, lunchtime and evening). On each recording occasion, subjects recorded the maximum pain experienced since the previous recording occasion using an 11 point numerical rating scale of pain intensity, PINRS (where 0 = no pain and 10 = worst pain imaginable). A lower score compared to Baseline indicates that the subjects experienced less severe pain on treatment than during Baseline. |
Baseline to 14 or 21 days
|
Sleep Interference Due to Pain in Treatment Period 2, Compared to Baseline
Time Frame: Baseline to 14 or 21 days
|
During Baseline and Treatment Period 2, subjects recorded sleep interference scores in their diary cards for each night (scores were recorded upon waking). Sleep Interference due to pain is scored using an 11 point numerical rating scale where 0 = pain does not interfere with sleep and 10 = completely interferes, unable to sleep due to pain. A lower sleep interference score compared to Baseline indicates that the subjects' pain interfered with sleep less on treatment than during Baseline. |
Baseline to 14 or 21 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Almena L Free, MD, Pinnacle Research Group LLC.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XPF-002-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inherited Erythromelalgia
-
PfizerCompletedInherited ErythromelalgiaUnited States
-
Xenon Pharmaceuticals Inc.CompletedInherited Erythromelalgia | Primary ErythromelalgiaNetherlands
-
BiogenCompletedPrimary Inherited ErythromelalgiaUnited States
-
VA Connecticut Healthcare SystemCompletedErythromelalgiaUnited States
-
Groupe Hospitalier Paris Saint JosephCompletedErythermalgiaFrance
-
AlgoTherapeutixCompleted
-
St. Olavs HospitalNorwegian University of Science and TechnologyRecruiting
-
Royal Brompton & Harefield NHS Foundation TrustBen Williams TrustUnknownInherited Cardiac Conditions
-
Manchester University NHS Foundation TrustRecruiting
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation Trust; Great Ormond Street Hospital...RecruitingCardiovascular Diseases | Inherited Cardiac ConditionsUnited Kingdom
Clinical Trials on XPF-002
-
Xenon Pharmaceuticals Inc.CompletedPostherpetic NeuralgiaUnited States
-
Xenon Pharmaceuticals Inc.CompletedHealthy Human VolunteersCanada
-
Xenon Pharmaceuticals Inc.CompletedDental PainUnited States
-
Xenon Pharmaceuticals Inc.Completed
-
Xenon Pharmaceuticals Inc.CompletedInherited Erythromelalgia | Primary ErythromelalgiaNetherlands
-
Baptist Health South FloridaCompletedOccupational Exposure to RadiationUnited States
-
Avalo Therapeutics, Inc.CompletedNon-Eosinophilic AsthmaUnited States
-
Xenon Pharmaceuticals Inc.CompletedHealthy Male VolunteersUnited Kingdom
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAcute Lung Injury | ARDS | COVID-19 PneumoniaUnited States
-
Avalo Therapeutics, Inc.TerminatedCrohn Disease | Ulcerative ColitisUnited States